Author:
Nations Kari R.,Bursi Roberta,Dogterom Peter,Ereshefsky Larry,Gertsik Lev,Mant Tim,Schipper Jacques
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Cutler NR, Sramek JJ, Murphy MF, et al. Critical pathways to success in CNS drug development. 1st ed. Oxford: Wiley-Blackwell, 2010
2. Sramek JJ, Cutler NR. Investigator perspective on MTD: practical application of an MTD definition — has it accelerated development? J Clin Pharmacol 2000; 40: 1184–7.
3. Ereshefsky L, Jhee S, Gertsik L, et al. Strategies to accelerate drug development for CNS compounds: focus on schizophrenia [poster]. 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15–18; Barcelona
4. Vanover K, Davis R, Ereshefsky L, et al. Safety, pharmacokinetics and early signals for efficacy of ITI-007, a novel investigational drug for the treatment of schizophrenia and related disorders [poster]. 13th International Congress on Schizophrenia Research; 2011 Apr 2–6; Colorado Springs (CO)
5. Cutler NJ, Sramek JJ. Guidelines for conducting bridging studies in Alzheimer’s disease. Alzheimer Dis Assoc Disord 1998; 12 (2): 88–92.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献